Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Study to Evaluate Bucillamine as a Potential Treatment for long COVID-19

Next Previous
Search
Trial Profile

A Phase 2 Study to Evaluate Bucillamine as a Potential Treatment for long COVID-19

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 07 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bucillamine (Primary)
  • Indications COVID 2019 infections
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 03 Feb 2025 According to a Revive Therapeutics media release, the Company continues to finalize the proposed Phase 2 study protocol for submission to the FDA. It expects to submit it by the end of Q1-2025. The proposed Phase 2 clinical study is expected to be approved by the FDA in Q2-2025.
    • 18 Sep 2024 According to a Revive Therapeutics media release, the company is finalizing the proposed Phase 2 study protocol for submission to the FDA. It expects to submit it by the end of 2024. The proposed Phase 2 clinical study is expected to be approved by the FDA in Q1-2025.
    • 12 Jun 2024 According to a Revive Therapeutics media release, The FDA has recommended that the evaluation of Bucillamine for Long COVID be submitted as a new Investigational New Drug (IND) application and may cross-reference applicable sections from current IND that evaluated the safety and efficacy of Bucillamine in patients with mild to moderate COVID-19 in a Phase 3 clinical trial. In addition, the FDA provided valuable feedback on the appropriate design, study population, and safety and

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top